U.K.-based medical charity LifeArc, and their partners, announced plans for investing $24 million (£18 million) to create cutting-edge gene therapy innovation hubs. The hubs—at King’s College London, NHS Blood and Transplant in Bristol, and the University of Sheffield—will provide GMP-grade manufacturing services, including viral vector production, to gene therapy developers from industry and academia. Academic gene therapy developers often lack the technical know-how needed to manufacture supplies for trials, the new network will aim to address this important need.